Pasithea Therapeutics Corp. KTTA 深 滬

Pasithea Therapeutics appoints chief medical officer

Pasithea Therapeutics (KTTA) said on Monday it appointed Kartik Krishnan as chief medical officer as it advances its lead candidate, PAS-004, which is a next-generation MEK inhibitor Krishnan will ove...

05-04 20:34

美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价

今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元

04-21 11:25

Pasithea Therapeutics Wins FDA Rare Pediatric Disease Tag For NF1 Drug Affecting ~115,000 Americans

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and

04-20 19:21

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

04-20 11:01

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Axe Compute (NASDAQ:AGPU) shares increased by 23.0% to $4.38 during We...

04-02 05:05

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics Corp. announced that the FDA has granted Fast Track designation to PAS-004 for the treatment of NF1-associated plexiform neurofibromas (PN) causing significant morbidity. This designation allows for frequent interactions with the FDA and rolling review to support expedited development. The company is currently conducting a Phase 1/1b clinical trial for PAS-004 in patients with NF1-associated PN.

04-01 11:01

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics Corp. announced that CEO Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb 26, 2026. The virtual presentation, scheduled for 4:00-4:30 PM ET, will discuss PAS-004, a next-generation MEK inhibitor for NF1-associated plexiform neurofibromas. A live webcast is available via the provided link, and a replay will be accessible shortly after. The Company is currently testing P...

02-17 12:01

Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

The latest update is out from Pasithea Therapeutics Corp ( ($KTTA) ). On Januar...

01-29 05:58

Pasithea Therapeutics Provided Updated Timelines on Its Ongoing Clinical Trials in Advanced Cancer and Adult NF1-PN Patients

Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565):Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the

01-13 20:08

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Corp. provided updates on its clinical trials for PAS-004, a next-generation MEK inhibitor for NF1-associated plexiform neurofibromas and advanced cancers. In the Phase 1/1b trial for NF1-PN, 12 patients were enrolled in the first four dose cohorts, with data expected in late 2026. The Phase 1 trial for advanced cancers plans to present long-term follow-up data from Cohorts 4 to 8 in Q2 2026. CEO Dr. Tiago Reis Marques highl...

01-13 12:01